ReviewJournal of magnetic resonance imaging : JMRI2015
Basic MR relaxation mechanisms and contrast agent design.
Review in Journal of magnetic resonance imaging : JMRI, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
73 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Evolving Characteristics of Gadolinium-Based Contrast Agents for MR Imaging: A Systematic Review of the Importance of Relaxivity.Journal of magnetic resonance imaging : JMRI · 2025Pooled it
- Imaging vascular and hemodynamic features of the brain using dynamic susceptibility contrast and dynamic contrast enhanced MRI.NeuroImage · 2019Pooled it
- Real-world evidence on gadoteridol safety: A 20-year FAERS database study revealing critical adverse reaction patterns.Medicine · 2026Article
- Early detection of invasive lung cancer and multiorgan metastasis by a collagen-targeted protein MRI contrast agent.Science advances · 2026Article
- Relaxivity of Gadobutrol and Gadoteric Acid in Cerebrospinal Fluid at 3T.Magnetic resonance in medicine · 2026Article
- [Fe-EOB-tCDTA] generates strong contrast in the blood but not in the liver, despite inhibiting cellular [Gd-EOB-DTPA]European radiology experimental · 2026Article
- Zwitterionic Mn(III)-Tetraphenyl Porphyrins: Water-Soluble MRI Contrast Agents with High Relaxivity.ChemMedChem · 2026Article
- Article
- Brain Tumor Imaging with Iopamidol CEST MRI: In Vivo Detection and Validation.Chemical & biomedical imaging · 2026Article
- Carbon Dots Meet MRI: Metal Doping for a Smart Contrast Agent Design.International journal of molecular sciences · 2026Review
- Convergent Evolution: Self-Assembly of Small Molecule, Polymeric, and Inorganic Contrast Agents toward Advanced MRI.Journal of the American Chemical Society · 2025Review
- Monitoring Pharmacological Treatment of Breast Cancer with MRI.Current issues in molecular biology · 2025Review
- Semiconducting Polymer Nanoparticles as Multimodal Agents for Optical and Magnetic Resonance Imaging.Advanced healthcare materials · 2025Review
- Signal Transduction Strategies for DNAzyme-Based Sensing and Imaging of Metal Ions in Cells andChemical & biomedical imaging · 2025Review
- Morphology Effect of PEGylated Iron Oxide Nanoparticles on the Enhancement of MRI Contrast Signal in Breast Cancer.ACS applied materials & interfaces · 2025Article
- Quantitative Interpretation of Transverse Spin Relaxation by Translational Diffusion in Liquids.The journal of physical chemistry. B · 2025Article
- Organic functionality in responsive paramagnetic nanostructures.Frontiers in chemistry · 2025Review
- Decoration of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) with N-oxides increases the TChemistryOpen · 2024Article
- Kilogram scale facile synthesis and systematic characterization of a Gd-macrochelate as TJournal of nanobiotechnology · 2024Article
- Feasibility and safety of contrast-enhanced magnetic resonance-guided adaptive radiotherapy for upper abdominal tumors: A preliminary exploration.Physics and imaging in radiation oncology · 2024Article
13 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The diagnostic capabilities of magnetic resonance imaging (MRI) have undergone continuous and substantial evolution by virtue of hardware and software innovations and the development and implementation of exogenous contrast media. Thirty years since the first MRI contrast agent was approved for clinical use, a reliance on MR contrast media persists, largely to improve image quality with higher contrast resolution and to provide additional functional characterization of normal and abnormal tissues. Further development of MR contrast media is an important component in the quest for continued augmentation of diagnostic capabilities. In this review we detail the many important considerations when pursuing the design and use of MR contrast media. We offer a perspective on the importance of chemical stability, particularly kinetic stability, and how this influences one's thinking about the safety of metal-ligand-based contrast agents. We discuss the mechanisms involved in MR relaxation in the context of probe design strategies. A brief description of currently available contrast agents is accompanied by an in-depth discussion that highlights promising MRI contrast agents in the development of future clinical and research applications. Our intention is to give a diverse audience an improved understanding of the factors involved in developing new types of safe and highly efficient MR contrast agents and, at the same time, provide an appreciation of the insights into physiology and disease that newer types of responsive agents can provide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.